Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
IPHA Sales of Investments
Cash received from selling or redeeming investments.
Innate Pharma S.A.NASDAQ: IPHA
Sales of Investments · Q4 FY2025 · quarter ended Dec 2025
Sales of investments declines year over year
Q4 FY2025 sales of investments of €7.33M fell 23.6% year over year. Over 3 fiscal years it compounded at +65.2% a year.
Context
- Sales of investments amounted to 484.9% of revenue in FY2025, up 408.9 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
EUR · from the cash flow
- Latest · FY2025
- 13.51M EUR
- Year-over-year change
- +40.9%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.51M | +40.9% |
| FY2024 | 2024-12-31 | 9.59M | -57.9% |
| FY2023 | 2023-12-31 | 22.77M | +658.9% |
| FY2022 | 2022-12-31 | 3M | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +40.9% is the highest of 6, against a peer median of -54.2%.
- Sales of investments amounts to 484.9% of revenue for IPHA, versus a peer median of 2099.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $138.92M USD | +29.2% | +11.5% | — | |
| LTM Mar 2026 | CHF 103.25M CHF | -59.1% | -11.6% | — | |
| LTM Mar 2026 | $67.84M USD | +28.1% | -17.5% | 12922.7% | |
| LTM Mar 2026 | $59.86M USD | -54.2% | +48.2% | 3355.7% | |
| LTM Mar 2026 | $26.75M USD | -65.8% | +107.4% | 844.1% | |
| FY2025 | €13.51M EUR | +40.9% | +65.2% | 484.9% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Dec 2025 | $0 USD | — | +3.4% | 0.0% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding IPHA) | — | -54.2% | +7.4% | 2099.9% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| Deferred Income Tax | (1.68M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.62M | 4.25M | 4.26M | 3.94M | 4.26M |
| Change in Working Capital | (9.88M) | (12.5M) | (32.09M) | 39.16M | (10.21M) |
| Accounts Receivables | 3.39M | (4.2M) | (13.67M) | 0 | 0 |
| Inventory | (6.27M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (946K) | (7.66M) | (3.89M) | 0 | 0 |
| Other Working Capital | (6.06M) | (636K) | (10.54M) | 39.16M | (10.21M) |
| Other Non-Cash Items | (1.3M) | 1.8M | (2.24M) | (2.53M) | (630.52K) |
| Operating Cash Flow | (58.46M) | (19.15M) | (32.56M) | (6.9M) | (50.67M) |
| Capital Expenditures | (1.33M) | (1.12M) | (2.35M) | (391K) | (134.47K) |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 4.8K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 3M | 22.77M | 9.59M | 13.51M |
| Other Investing Activities | 406K | (1K) | (1.79M) | 1K | (6.38M) |
| Investing Cash Flow | (917K) | 1.88M | 20.63M | 9.2M | 7M |
| Debt Repayment | 26.63M | (2.03M) | (2.36M) | (8.94M) | (8.56M) |
| Common Stock Issued | 499K | 198K | 395K | 2.93M | 14.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187K | 198K | 395K | 2.93M | 0 |
| Financing Cash Flow | 26.82M | (1.83M) | (1.97M) | (6.01M) | 5.83M |
| Effect of Forex Changes | (483K) | (428K) | 274K | (505K) | 7.41M |
| Net Change in Cash | (33.04M) | (19.53M) | (13.62M) | (4.21M) | (30.44M) |
| Free Cash Flow | (59.79M) | (20.28M) | (34.91M) | (7.29M) | (50.81M) |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.